+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

L

Actively Recruiting

This research aims to evaluate the long-term safety and efficacy of APG777 in adults with moderate-to-severe atopic dermatitis who have already completed treatment in a prior APG777 study. The study is a multicenter, double-blind, phase 2 extension designed for participants who, according to the investigator, could benefit from continued APG777 treatment. The study consists of three periods a Screening Visit coinciding with the last visit of the parent studys Maintenance Period an Extended Treatment Period where participants maintain their APG777 dose from the previous study or receive open-label APG777 if they did not meet certain response criteria and a Post-treatment Follow-up Period. Participants receive APG777 as subcutaneous injections every 12 or 24 weeks, depending on their previous dosing regimen or study arm assignment. During the study, participants will have assessments for safety and efficacy, including monitoring treatment-emergent adverse events for up to 3 years. Researchers will also track improvements in eczema severity, itch symptoms, use of rescue therapy, and serum drug concentrations over an average of 2 years during the Extended Treatment Period. Participation may last up to 3 years, including follow-up to observe long-term outcomes.

Age: 18Years +All GendersPhase 2
80 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of dotinurad compared with allopurinol in lowering serum uric acid levels in adults with gout-related hyperuricemia. This Phase 3 randomized study focuses on measuring the proportion of participants achieving target serum uric acid levels at Week 24. It aims to provide insights into treatment options for people living with gout. Participants will be randomly assigned to one of three groups one group will continue allopurinol at their current stable dose once daily through Week 64, while the other two groups will receive dotinurad with dose escalation over time. Dotinurad dosing starts at 1 mg daily for the first 4 weeks, increasing to 2 mg daily through Week 64 for one group, and for the other group, it increases from 1 mg daily for 4 weeks to 2 mg daily for 8 weeks, then 4 mg daily through Week 64. Throughout the study, participants will undergo regular assessments including serum uric acid level measurements and gout flare monitoring from baseline through Week 68. Safety will also be tracked by recording adverse events. The main outcome is the percentage of participants with serum uric acid below 6.0 mgdL at Week 24. The total study duration per participant extends up to approximately 68 weeks, with ongoing evaluations to assess gout flare frequency and other relevant outcomes.

Age: 18Years - 75YearsAll GendersPhase 3
119 locations
P

Actively Recruiting

Researchers are studying the effectiveness of dotinurad compared to allopurinol in lowering serum uric acid levels in adults with tophaceous gout. This Phase 3, randomized, double-blind trial focuses on adults aged 18 to 75 years diagnosed with gout for at least one year who have measurable tophi. The study aims to evaluate how well dotinurad lowers uric acid at Week 24 compared to allopurinol. Participants are divided into two groups. One group stops their current allopurinol and takes study-provided allopurinol once daily up to Week 76. The other group stops their prior allopurinol and starts dotinurad, beginning with 1 mg daily for the first 4 weeks, increasing to 2 mg daily for 8 weeks, then 4 mg daily through Week 76. Both treatments involve oral capsules taken once a day. This approach allows comparison of the two drugs effects over an extended treatment period. During the study, participants will have regular assessments to monitor serum uric acid levels, tophi response, and gout flare frequency up to Week 80. Safety is tracked by recording any adverse events. Data collected will include changes in uric acid, tophi area, and flare rates. Participants remain in the study for over a year, with frequent visits for evaluations and treatment adherence checks.

Age: 18Years - 75YearsAll GendersPhase 3
96 locations
E

Actively Recruiting

Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.

Age: 12Years - 63YearsAll GendersPhase 3
272 locations
E

Actively Recruiting

Researchers are conducting a Phase 2 randomized, double-masked, vehicle-controlled study to evaluate the safety and effectiveness of DFL24498 topical ophthalmic solution compared to a vehicle solution in adults with dry eye disease. Approximately 417 participants aged 18 years or older will be enrolled across multiple sites in the US. The study aims to understand how the treatment affects dry eye symptoms and eye health over 16 weeks. Participants will be randomly assigned to receive either DFL24498 or a vehicle solution, both administered as one drop in each eye four times daily for 12 weeks. The study includes three periods within the total 16 weeks, including treatment and follow-up phases. The treatments are applied topically to the eyes under controlled conditions to compare their effects. During the study, participants will undergo assessments such as corneal fluorescein staining using the National Eye Institute scale, symptom evaluations with the Symptom Assessment in Dry Eye questionnaire, tear production tests, and conjunctival staining. Safety will be monitored through reports of adverse events up to week 14. Visual acuity and other ocular measurements will be regularly checked to monitor treatment impact and participant health throughout the study.

Age: 18Years +All GendersPhase 2
24 locations
L

Actively Recruiting

This research aims to evaluate the long-term safety and effectiveness of ORKA-001 in adults who have moderate-to-severe plaque psoriasis and previously took part in an Oruka Therapeutics study. It is an open-label extension study where all participants receive the study drug to monitor ongoing treatment effects and safety over an extended period. Participants will receive ORKA-001 as a subcutaneous injection through different dosing schedules once a year high or low dose, twice a year, or no drug until meeting specific response criteria. The treatment period can last up to about 96 weeks, followed by a post-treatment follow-up lasting approximately 48 weeks after the last study visit. During the study, participants will undergo safety monitoring, including checking for adverse events. Effectiveness will be assessed by measuring skin condition improvements using tools like the Psoriasis Area and Severity Index PASI and Investigators Global Assessment IGA. The team will track these results over time to understand how participants maintain their skin improvements and overall treatment tolerance.

Age: 18Years +All GendersPhase 2
39 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a group B streptococcus GBS vaccine in healthy pregnant women and their babies. This Phase 3 randomized, placebo-controlled, double-blinded study involves pregnant participants aged 49 or younger between 24 and 36 weeks of pregnancy, without major fetal abnormalities or infections such as HIV, syphilis, or hepatitis B. The study aims to understand how the GBS vaccine works and its safety profile for both mothers and infants. Participants will receive a single injection of either a multivalent GBS vaccine GBS6 or a placebo saline. After birth, a subset of infants will participate for up to 19 months, receiving standard vaccines including diphtheria toxoid-containing and pneumococcal vaccines as per local immunization schedules. Blood samples will be collected from infants after completing primary and booster vaccinations to assess immune responses. Pregnant participants will attend at least 3 to 4 visits with some allowed by telephone, with follow-up continuing for up to six months after delivery. Infants will be monitored for about 12 months, including a subset with extended follow-up to 19 months. Researchers will evaluate adverse events, antibody levels, and immune responses in both mothers and infants to assess safety and potential protection provided by the vaccine.

Age: 1Day - 49YearsAll GendersPhase 3
219 locations
C

Actively Recruiting

Researchers are evaluating how binge eating episodes are recorded using two different types of diaries a paper diary and an electronic diary. The study aims to determine if both formats collect information in the same way and to understand which diary type is easier for participants to use. This research addresses the need for reliable and user-friendly tools to track binge eating behavior in adults with Binge Eating Disorder. Participants will complete one diary format for two weeks and then switch to the other format for another two weeks. This crossover design allows comparison between the paper diary completed daily in the evening and the electronic diary accessed via a smartphone app. The study focuses on how these diaries capture binge eating episodes and their usability. During the study, participants will record binge eating episodes daily using each diary format for two-week periods. Researchers will compare the number of binge episodes recorded over 14 days between the two diary types. Participants must own a compatible smartphone to use the electronic diary and will complete self-report measures. The trial includes assessments to confirm binge eating episodes and monitors completion and usability of both diary formats throughout the 30-day participation period.

Age: 0 - 18YearsAll GendersPhase Not Applicable
1 location
O

Actively Recruiting

Researchers are observing adults diagnosed with schizophrenia in the United States who have started treatment with xanomeline and trospium chloride KarXT. The study aims to describe real-world treatment patterns, effectiveness, and adverse events related to KarXT use in routine clinical care. Participants are those who have initiated KarXT treatment within 16 weeks with plans to discontinue prior antipsychotic treatments or are on stable antipsychotic regimens planning to switch to KarXT. The study follows these participants for up to 20 weeks to record treatment titration, switches, and continuation patterns. Concomitant psychiatric medications may continue at stable doses during the study. During the study, researchers collect data on adverse events, weight changes, clinical global improvement scores, schizophrenia-related relapses, treatment discontinuation reasons, and use of antiemetic treatments for gastrointestinal symptoms. Baseline information includes demographics, family history, diagnosis duration, and previous treatments. This observational study supports understanding KarXT treatment in real-world settings up to 20 weeks after initiation.

Age: 18Years +All Genders
68 locations
P

Actively Recruiting

Researchers are evaluating the effects and safety of solriamfetol in adults with binge eating disorder BED. This Phase 3 trial compares two doses of solriamfetol 150 mg and 300 mg with a placebo to better understand their impact on BED symptoms. Participants must be aged 18 to 55 with a diagnosis of BED based on DSM-5 criteria. Participants will be randomly assigned to one of three groups receiving either solriamfetol 150 mg, solriamfetol 300 mg, or placebo tablets, all taken once daily for 12 weeks. This randomized, double-blind study will assess how these treatments affect binge eating episodes over the course of the trial. During the 12 weeks, participants will be monitored for changes in the number of binge eating episodes. Safety and efficacy will be evaluated through regular assessments. All study-related care, including medication and visits, will be provided at no cost, and the total participation duration is approximately 12 weeks.

Age: 18Years - 55YearsAll GendersPhase 3
45 locations

1-10 of 18

1